Business & Economics

AbbVie Announces $1.4 Billion Manufacturing Campus in North Carolina: Largest Single-Site Investment in Company History

Recent Advances in the Clinical Development of First- and Best-in-Class Antibody-Drug Conjugates: Pipeline Update from Adcendo

The landscape of cancer treatment is rapidly evolving, driven by relentless innovation and a deepening understanding of tumor biology. Among the leading developers in this revolution is Byondis, an independent Dutch biopharmaceutical company with a bold mission: to deliver breakthrough solutions for patients with cancer through the creation of innovative, targeted medicines.

Gilead Accelerate Its Oncology ADC Pipeline by Acquiring Tubulis for $5B

Akari Therapeutics and WuXi XDC have announced a significant strategic partnership to accelerate the development and clinical entry of Akari’s lead ADC program, AKTX-101, which leverages PH1 (PH-1), a novel RNA splicing-modulating payload, for the treatment of metastatic urothelial cancer.

Economy: Failure to Reshore Pharmaceutical Manufacturing: US Approved Drug Manufacturing Shifts to Europe as US Deal Volume Drops

Samsung Biologics Expands Global Footprint with Acquisition of GSK’s Rockville Manufacturing Facility

The first patient (FIP) has been dosed in a Phase 1 clinical trial combining IDE849 (also known as SHR-4849), a potential first-in-class delta-like ligand 3 (DLL3)-targeting  Topoisomerase I (Topo-I-) payload antibody drug conjugate (ADC), with IDE161, a potential first-in-class poly(ADP-ribose) glycohydrolase (PARG) inhibitor. Both drugs are being developed by IDEAYA Biosciences. The Phase 1 combination study will be evaluated in DLL3 upregulated solid tumor indications, including small cell lung cancer (SCLC), neuroendocrine tumors (NETs), neuroendocrine carcinomas (NECs), and melanoma.

Industry Report: Lotte's Strategic Rise as a Global CDMO Amid Industry Shifts

AbbVie and RemeGen to Jointly Develop a Novel Bispecific Antibody for Advanced Solid Tumors